ABCB6 mutations impact the pharmacokinetics of drugs like cyclophosphamide and doxorubicin by affecting their absorption into cells and intracellular storage, which influences the drugsâ€™ effectiveness and toxicity. This variation in drug handling due to ABCB6 can significantly alter the therapeutic efficacy and side effects of these chemotherapeutic agents, underscoring the importance of genetic considerations in cancer treatment planning.